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ARTICLE
Engineered niches support the development of
human dendritic cells in humanized mice
Giorgio Anselmi1,2,7, Kristine Vaivode1,2, Charles-Antoine Dutertre3, Pierre Bourdely1,2,
Yoann Missolo-Koussou 4, Evan Newell3, Oliver Hickman1,2,8, Kristie Wood5,9, Alka Saxena5, Julie Helft 4,
Florent Ginhoux 3 & Pierre Guermonprez1,2,6✉
Classical dendritic cells (cDCs) are rare sentinel cells specialized in the regulation of adaptive
immunity. Modeling cDC development is crucial to study cDCs and harness their therapeutic
potential. Here we address whether cDCs could differentiate in response to trophic cues
delivered by mesenchymal components of the hematopoietic niche. We find that
mesenchymal stromal cells engineered to express membrane-bound FLT3L and stem cell
factor (SCF) together with CXCL12 induce the specification of human cDCs from CD34+
hematopoietic stem and progenitor cells (HSPCs). Engraftment of engineered mesenchymal
stromal cells (eMSCs) together with CD34+ HSPCs creates an in vivo synthetic niche in the
dermis of immunodeficient mice driving the differentiation of cDCs and CD123+AXL+
CD327+ pre/AS-DCs. cDC2s generated in vivo display higher levels of resemblance with
human blood cDCs unattained by in vitro-generated subsets. Altogether, eMSCs provide a
unique platform recapitulating the full spectrum of cDC subsets enabling their functional
characterization in vivo.
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C lassical human dendritic cells (cDCs) are sentinels of theimmune system with a unique ability to regulate the func-tion of T lymphocytes1. Dendritic cells (DCs) can induce
immune tolerance2 or drive the development of immunity3.
The analysis of blood circulating subsets has revealed that cDCs
consist in two major subtypes: CD141+XCR1+Clec9A+ DCs
(cDC1) and CD1c+CD11c+CD172a (SIRPα)+ DCs (cDC2s)4–6.
Both cDC1s and cDC2s arise from a bone marrow committed
progenitor7 or from early IRF8+ multipotent progenitors8,9, which
generate a common circulating precursor10 that progressively
diverge in pre-cDC1s and pre-cDC2s10–12. Type 1 DCs are con-
served between mouse and human, and they share the expression of
specific surface markers such as Clec9A13 and XCR15, as well as the
transcription factor (TF) IRF8, which is essential for the develop-
ment of murine cDC1s4–6,13–15. Conversely, human CD1c+ type 2
DCs have been shown to express the IRF4 TF16, which controls the
development of their phenotypic equivalent in the mouse
model16,17. This rather simple picture is complicated by the
diversity of CD1c+ cells, which encompass migratory DCs and
CD14int inflammatory DCs recruited during inflammation18,19.
More recently, unbiased approaches have uncovered a deeper
complexity in the DC network with the identification of two types
of cDC2s with distinct transcriptional profiles and the identification
of AXL+CD11c+CD1c+ cells, which have been proposed to act as a
precursor for cDCs12,20.
Human hematopoietic progenitors reside in the stem cells
niche of the bone marrow. Genetic studies in the murine model
identified three essential factors supporting HSPCs homeostasis:
the membrane-bound form of stem cell factor (SCF/KITL)21,22,
the C-X-C motive chemokine 12 (CXCL12)23,24 and thrombo-
poietin (TPO)25,26. In the bone marrow, perivascular mesench-
ymal stromal cells have been described as the main source of SCF
and other niche factors27. At steady state, Flt3-ligand (FLT3L) is
delivered as a membrane-bound precursor expressed on radio-
resistant stromal cells28–30. After egressing from the bone mar-
row, DC precursors circulate in the blood and seed the peripheral
tissues31. In the lymph node, stromal fibroblastic reticular cells
provide FLT3L32 and FLT3-dependent proliferation of cDC in
periphery is required for their maintenance33,34.
Modeling the development of cDCs in culture systems is
instrumental to better understand their ontogeny and define their
immunological function. Pioneer work from Banchereau et al.35
have identified that granulocyte–macrophage colony-stimulating
factor (GM-CSF) and tumor necrosis factor-α (TNF-α) cooperate
to produce CD1a+ cells with features of Langerhans cells from
CD34+ hematopoietic stem and progenitor cells (HSPCs). Sal-
lusto et al.36 have shown that GM-CSF and interleukin (IL)-4
induce the differentiation of CD1c+CD1a+ inflammatory DCs
from CD14 monocytes. More recent work has demonstrated that
FLT3L (with TPO or with SCF/KITL, GM-CSF, and IL-4) is
instrumental in generating CD141+ cDC1s aligning phenotypi-
cally and functionally with cDC1s7,8,37–39. This is in line with the
crucial role of FLT3L, engaging the Flt3 receptor tyrosine
kinase40,41 in controlling DC homeostasis both in mice31,33,42,43
and humans10,28,44,45. Moreover, the activation of Notch signal-
ing pathway has been shown to further improve the in vitro
differentiation of both human and mouse cDC1s46,47. Despite the
successes in modeling cDC1 differentiation in vitro, CD1c+ cells
found in culture of CD34+ HSPCs either align poorly with
bona fide blood circulating cDC2s38 or were not extensively
characterized46,47.
Recapitulating human cDC development in vivo has the
potential to greatly improve our understanding of DC biology
and facilitate its translational applications. Human cDCs have
been found in stably reconstituted humanized mice treated
with supraphysiological concentration of human FLT3L28,48,49.
However, the generated CD11c+CD141+ and CD11c+CD1c+
cells were poorly characterized and their dissemination to per-
ipheral tissues has rarely been assessed50.
Here we aimed at modeling human cDC development by
providing physiological factors associated to hematopoietic
niches. We found that engineered mesenchymal stromal cells
(eMSCs) expressing a combination of membrane-bound FLT3L
and SCF/KITL together with CXCL12 provide a scaffold for
human cDC differentiation. Engraftment of eMSCs along with
CD34+ HSPCs leads to the local development of cDCs in
immunodeficient mice. This in vivo system recapitulates the
differentiation of not only pDCs, cDC1s, and cDC2s but also pre/
AS-DCs, and reaches an unmatched level of similarity of the
generated cDC2s with their blood counterparts.
Results
Transmembrane FLT3L drives human DC differentiation
in vitro. We hypothesized that the interaction of hematopoietic
progenitors with membrane-bound factors expressed by stromal
cells of the niche would promote the specification of the cDC
lineage.
To test this, we engineered a bone marrow-derived murine
mesenchymal cell line (MS5)7,51 to stably and homogeneously
express the transmembrane form of human FLT3L (MS5_F) as
probed by flow cytometry (Fig. 1a). Co-culture of MS5_F with
CD34+ HSPCs drives the appearance of cDC1-like Clec9A+
CD141+ and cDC2-like CD14−CD1c+ cells. Importantly, MS5_F
is more efficient than recombinant soluble FLT3L (MS5+ recFL)
in generating cDC-like cells (Fig. 1b).
In contrast, OP952 hematogenic stromal cells stably expres-
sing membrane-bound FLT3L (OP9_F) were less efficient than
MS5_F in driving cDC differentiation (Fig. 1c). Besides, MS5_F
also promoted the appearance of CD123+CD303/4+ cells
resembling either pDCs or pre/AS-DCs12,20 (Supplementary
Fig. 1a, b).
Next, we wanted to test whether cell-to-cell interactions
mediate the differentiation of cDCs driven by FLT3L-expressing
MS5 stromal cells. Using transwell permeable to soluble factors
but preventing cognate interactions, we found that direct contact
is required to support efficiently cDC differentiation (Fig. 1d).
Collectively, these data show that membrane FLT3L expression
in stromal cells provide an improved platform to trigger the
differentiation of cDC-like cells from CD34+ HSPCs in vitro via
cell-to-cell contact.
CXCL12 and SCF improve FLT3L-driven DC differentiation.
Next, we sought to improve the efficiency of cDC production in
MS5_F by co-expressing additional niche factors. We focused on
SCF, CXCL12, and TPO because of their essential role in sup-
porting HSPCs maintenance in the bone marrow niche21,23–26,53.
SCF had also been extensively used in previously published DC
culture protocols7,38,39,54.
To this end, we generated a collection of MS5 stromal cells
stably expressing either one, two, three, or four human factors by
combining CXCL12, TPO, and membrane-bound SCF/KITL,
with or without membrane-bound FLT3L (Supplementary
Fig. 2a).
We screened this collection of eMSC lines based on their ability
to support human cDC differentiation from cord blood-derived
CD34+ HSPCs.
At day 15, only FLT3L-expressing eMSCs successfully
supported the differentiation of CD141+Clec9A+ and CD14−
CD1c+ cells (Fig. 2a and Supplementary Figs. 2b and 3a). We
conclude that FLT3L is necessary for the differentiation of cDCs
using eMSCs. Besides, optimal cDC production was obtained in
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Fig. 1 Transmembrane FLT3L drives human DC differentiation in vitro. a Expression of membrane-bound FLT3L in mouse bone marrow-derived stromal
cells engineered to express human FLT3L (MS5_F) and control (MS5_CTRL). b Human cDC subsets differentiated in vitro from CD34+ cord blood-derived
HSPCs cultured with MS5 expressing membrane-bound FLT3L (MS5_F) or MS5 supplemented with recombinant human FLT3L (MS5+recFL) at day 15
(n= 3 donors in one experiment). *p < 0.05, **p < 0.01, ***p < 0.001, one-way ANOVA test with Tukey’s multiple comparisons. c Representative flow
cytometry plots and quantification of human cDC subsets differentiated in vitro from cord blood-derived CD34+ progenitors in culture with mouse stromal
cell lines MS5 and OP9 expressing human FLT3L (MS5_F and OP9_F) at day 15 (n= 4 donors in one experiment). *p < 0.05, one-way ANOVA test with
Tukey’s multiple comparisons). d Absolute number and frequency of CD141+Clec9A+ and CD14−CD1c+ human cDCs differentiated from CD34+ HSPCs in
direct contact (lower well) or physically separated (upper well) from engineered MS5_F. DC differentiation was assessed at day 15 by flow cytometry (n=
6 donors in three independent experiments). *p < 0.05, two-tailed paired Student’s t-test. Data are presented as floating bars ranging from min to max and
line represents median (b–d).
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cultures containing eMSC co-expressing membrane-bound SCF
and CXCL12 together with FLT3L (MS5_FS12) (Fig. 2a), whereas
no difference was observed for CD14+CD16− monocytes and
CD14+CD16+ macrophages as compared to MS5_CTRL (Sup-
plementary Fig. 3b).
Furthermore, we noticed that in vitro differentiated CD14−
CD1c+ cDC2-like cells were heterogeneous for the expression of
the mannose receptor CD206 (Fig. 2a). Circulating blood cDC2s
do not generally express CD206 (Supplementary Fig. 3c), whereas
CD206 is a marker of skin and migratory cDC219,55.
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Fig. 2 CXCL12 and SCF improve FLT3L-driven DC differentiation. a Representative FACS plots and absolute number of CD141+Clec9A+, CD1c+CD206−,
and CD1c+CD206+ cells generated from CD34+ HSPCs cultured with MS5 expressing human FLT3L (MS5_F) in combination with human SCF (S), TPO
(T), and CXCL12 (12). Day 15 flow cytometry analysis of n= 3 cord blood donors in three independent experiments. *p < 0.05, one-way ANOVA test with
Tukey’s multiple comparisons. b ELISA detecting human GM-CSF in the supernatant of CD34+ HSPCs cultured with engineered MS5 expressing human
FLT3L, SCF and CXCL12 (MS5_FS12) at day 15 for n= 2 (MS5_CTRL ± CD34+ HSPC and MS5_FS12 only) and n= 4 (MS5_FS12+ CD34+ HSPC)
independent donors. c Absolute number of human DC subsets generated in vitro from CD34+ HSPC using MS5_FS12 stromal cells in the presence of
human GM-CSF neutralizing antibody as compared to isotype control (n= 6 independent donors in two experiments). Data are presented as floating bars
ranging from min to max and line represents median a, c or as bar graphs with mean ± SEM (b).
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Most of the previously described protocols to generate
human DC-like cells in vitro from both CD14+ monocytes
and CD34+ HSPCs made an extensive use of the cytokine GM-
CSF7,8,36,38,39,54, with one exception47. As we did not include
GM-CSF in our protocol, we wanted to assess whether human
GM-CSF was spontaneously produced in CD34+ cultures. We
could not detect any GM-CSF from co-culture supernatant
(Fig. 2b). Accordingly, GM-CSF-blocking antibody did not
impact the generation of cDCs driven by MS5_FS12 (Fig. 2c).
We conclude that GM-CSF is dispensable for the generation of
cDCs in vitro, as previously reported in both mouse56,57 and
human47.
We also observed that MS5_FS12 stromal cells significantly
improve the differentiation of CD123+CD303/4+ cells (Fig. 3a), a
phenotype shared by both plasmacytoid DC and pre/AS-DC12,20.
A more refined phenotypic characterization of the in vitro-
generated cells also shows that all CD123+ cells express high
levels of CD45RA and they can be subdivided in AXL−CD327lo/−
and AXL+CD327+ subsets, phenotypically aligning to pDC and
pre/AS-DC (Fig. 3b). This conclusion was further supported by
gene set enrichment analysis (GSEA)58 of RNA-sequencing
(RNA-seq) data, displaying a significant enrichment of previously
reported pDC and AS-DC gene signatures20 in in vitro-generated
AXL−CD327lo/− and AXL+CD327+, respectively (Fig. 3c).
Moreover, only the AXL−CD327lo/− cells were capable to
produce type I interferon in response to toll-like receptor (TLR)
stimulation, a specific feature of bona fide pDC, which is not
shared with pre/AS-DC12,20 (Fig. 3d).
In conclusion, we identified the combination of membrane-
bound FLT3L, SCF, and CXCL12 (MS5_FS12) as the most
efficient tested condition to support human DCs differentiation
in vitro from CD34+ HSPCs.
Human DC generated in vitro align with circulating blood DC.
To validate the identity of the cDCs generated using the
MS5_FS12 stromal niche, we compared the transcriptome (RNA-
seq) and phenotype (CyTOF) of in vitro-differentiated subsets to
circulating blood cDC1s and cDC2s (Fig. 4a–f).
Hierarchical clustering of RNA-seq data revealed that subsets
generated in culture maintain a strong “culture imprinting”
(Supplementary Fig. 4a). Indeed, we could identify a 2000 genes
signature (1000 genes up- and 1000 genes downregulated), which
clearly separates in vitro-generated cells from circulating blood
subsets regardless of their subset identity (Supplementary Fig. 4b).
The majority of these genes were associated to cell cycle and
metabolism as shown by pathways enrichment analysis (Supple-
mentary Fig. 4c). Nonetheless, once this “in vitro culture
signature” was subtracted from the total protein coding genes,
CD141+Clec9A+ and CD1c+CD206+/− cells generated in
culture transcriptionally align to blood cDC1 and cDC2,
respectively (Fig. 4a).
To further validate the similarity of in vitro generated cells with
physiologically circulating subsets, we performed GSEA58 using
the BubbleGum software59. This methodology enables to score
the enrichment of a signature in a pairwise comparison of two
transcriptomes. We scored cDC1 alignment using gene signatures
specific for blood cDC1 obtained from published datasets
(cDC1>CD1c[+ 60 and DC1>ALL20). CD14−CD1c+ cells have
recently been shown to contain two distinct subsets termed as
cDC2 and cDC320. Alignment of cultured cells was probed
towards total CD1c+ cells (CD1c>cDC1), cDC2 (cDC2>ALL and
cDC2>DC3), and DC3 signatures (DC3>cDC2 and DC3>ALL).
We found that in vitro-generated CD141+Clec9A+ and CD1c+
CD206+/− cells are enriched in genes defining circulating blood
cDC1 and cDC2, respectively (Fig. 4b). The expression of the top
50 genes for each signature in the differentiated subsets further
supports this conclusion (Fig. 4c). Importantly, both CD206+ and
CD206− subsets aligned preferentially to cDC2 as compared with
DC3 and cDC1 (Fig. 4b and Supplementary Fig. 4d). CD163 was
recently described as a marker selectively expressed in blood
cDC3 as compared with cDC220. Supporting our previous
conclusion, CD163 was neither expressed in CD1c+CD206−
nor in CD1c+CD206+ cells generated in vitro, whereas CD163+
cells were detected among CD14+ monocytes and CD14+CD16+
macrophages (Supplementary Fig. 4e).
To obtain a more exhaustive characterization of the phenotype
of in vitro-generated subsets, we performed CyTOF analysis using
a panel of 38 metal-conjugated monoclonal antibodies. Dimen-
sion reduction of the CyTOF data was performed using the
Uniform Manifold Approximation and Projection (UMAP)
algorithm61. UMAP plots display clusters of cells that were
expanded upon MS5_FS12 co-culture as compare to MS5_CTRL
(Fig. 4d). Clec9A+CD141+ cells identified by flow cytometry
were shown to also express CADM1 and CD26 further aligning
them with blood cDC1s (red cluster, Fig. 4d–f). CD14−CD1c+
cells did not express high level of monocyte markers such as
CD64, CD68, and CD16, whereas they appeared heterogeneous
for CD206 expression (blue cluster, Fig. 4d–f and Supplementary
Fig. 4f). Of note, CD14−CD1c+ cells generated in culture did not
express high level of FcεRIa, CD172a, and CD5 found in blood
cDC2s (Supplementary Fig. 4f). By contrast, they were strongly
positive for CD86 and CD80 unlike their circulating counterpart
(Supplementary Fig. 4f). In addition, CD123+CD303+ cells were
shown to express heterogeneous levels of pre-DC markers such as
CD327 and CX3CR1, and moderate level of AXL (green cluster,
Fig. 4d–f and Supplementary Fig. 4f), in line with flow cytometry
analysis highlighting the presence of both pDC and pre/AS-DC
within CD123+CD303+ cells generated in vitro (Fig. 3b). On the
other hand, by combining flow and mass cytometry analysis, we
were able to show that MS5_FS12 stromal cells do not support
lymphoid development (Fig. 4d and Supplementary Fig. 4g).
Indeed, the remaining cells (other than DC) present in culture
consist of CD15+ Granulocytes and CD14+CD16+/− Monocytes/
Macrophages (Supplementary Fig. 4h). Finally, the analysis of
in vitro cDC differentiation kinetics revealed that both cDC1 and
cDC2 can be detected in MS5_FS12 cultures as early as day7
(Supplementary Fig. 4i). However, the yield of in vitro generated
cDC was significantly higher at day14, when most of the cultures
were therefore analyzed (Supplementary Fig. 4i).
Collectively, our data demonstrate that: (i) in vitro-generated
CD141+Clec9A+ recapitulate the phenotype of bona fide blood
cDC1; (ii) CD14−CD1c+ cells align to cDC2 regardless of their
CD206 expression; (iii) CD123+CD303+ cells contain some
recently described pre-DC/AS-DC phenotypically and function-
ally distinct from pDCs. However, we identified two major
limitations of the in vitro culture. First, the culture system
imposes a strong transcriptional imprinting throughout subsets.
Second, in vitro-generated cDC2s failed to express to full
phenotypic profile of blood cDC2s.
Engineered stromal niches support HSPC maintenance in vivo.
We next wanted to assess whether we could use MS5_FS12 to
recapitulate a more physiological niche microenvironment sup-
porting human HSPCs maintenance in vivo.
To this end, we designed an experimental strategy based on
the subcutaneous injection of cord blood-derived CD34+
HSPCs together with MS5_FS12 in a basement membrane
matrix (Matrigel) in NOD.Cg-Prdcscid Il2rgtm1Wjl/SzJ (NSG)
mice (Fig. 5a).
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Clusters of cells embedded in Matrigel can be identified as early
as day 12 by tissue histology (Fig. 5b). Flow cytometry analysis
demonstrated that MS5_FS12 but not MS5_CTRL induced the
expansion of human leukocytes within the Matrigel plugs
(Fig. 5c). We then tested whether cell-to-cell interactions of
eMSC with human progenitors play a role in this process. We
injected two independent plugs of CD34+ HSPCs with either
MS5_CTRL or MS5_FS12 in the same recipient mouse
(contralateral plugs) (Fig. 5d). We found a relative expansion of
human leukocytes in MS5_FS12 as compared to MS5_CTRL
contralateral plugs (Fig. 5d). We conclude that MS5_FS12 does
not efficiently provide soluble factors enabling human leukocytes
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expansion systemically. Therefore, we hypothesized that
membrane-bound FLT3L and SCF together with CXCL12 define
an efficient in vivo niche by delivering cell-to-cell contacts
supporting HSPCs expansion. Supporting this hypothesis, we
found that MS5_FS12 expressing GFP persist in the plugs at day
12 of differentiation (Fig. 5e). Immunofluorescence analysis
further supported this observation and demonstrated the
existence of cell-to-cell contact between MS5_FS12 and human
CD45+ leukocytes (Fig. 5e and Supplementary Fig. 5a). Leuko-
cytes expressing CD34+ could also be detected, supporting the
notion that a pool of undifferentiated progenitors is maintained
in the MS5_FS12 organoids at day 12 (Fig. 5e). Of note, Matrigel
plugs contained mouse CD31+ cells, suggesting undergoing
vascularization as evidenced by the formation of early tube-like
structure (Fig. 5f). However, no vascular leak was observed,
as demonstrated by the absence of intravenously delivered
CTV+CD3+ cells in the subcutaneous plug (Supplementary
Fig. 5b).
Taken together, these data show that engineered stromal cells
MS5_FS12 provide a minimal synthetic niche scaffold supporting
human CD34+ HSPCs maintenance and expansion in vivo.
The MS5_FS12 niche supports human DC development
in vivo. We investigated whether the engraftment of CD34+
HSPCs together with MS5_FS12 could lead to the local differ-
entiation of human DC subsets.
Flow cytometry analysis of Matrigel organoids demonstrates
that the MS5_FS12 but not the MS5_CTRL niche specifically
supports the differentiation of CD141+Clec9A+ cDC1-like cells
and CD14−CD1c+ cDC2-like cells (Fig. 6a and Supplementary
Fig. 6a). This finding was supported by immunofluorescence
staining on plug sections highlighting the occurrence of human
CD45 cells expressing either Clec9A or CD1c (Fig. 6b).
Further analysis revealed the expansion of CD123+CD303/4+
cells in MS5_FS12 when compared to MS5_CTRL plugs (Fig. 6c and
Supplementary Fig. 6a). All these cells also expressed CD45RA and
heterogeneous levels of AXL and CD327, as previously described for
their in vitro counterparts (Fig. 6c). However, only MS5_FS12
induced a strong accumulation of AXL+CD327+ pre/AS-DC
expressing various levels of CD1c (Fig. 6c). In addition, bona
fide CD123+CD45RA+AXL−CD327lo/- pDCs could also be
detected (Fig. 6c). RNA-seq analysis of in vivo-generated CD123+
AXL−CD327lo/− and CD123+AXL+CD327+ cells further support
this conclusion and unequivocally align them to blood circulating
pDC and AS-DC, respectively (Fig. 6d).
To further refine the phenotypic characterization of HLA-DR+
mononuclear phagocytes in MS5_FS12 organoids we performed
high-dimensional mass cytometry analysis. The comparison of
MS5_FS12 with MS5_CTRL plugs highlighted the expansion of
all subsets previously identified by flow cytometry: cDC1s, cDC2s,
pre/AS-DCs, pDCs, and a distinct population of CD33+
CCR2+CX3CR1+Clec12A+ myeloid cells (Fig. 6e and Supple-
mentary Fig. 6b). We next wanted to determine whether
commitment towards the cDC lineage would be dependent on
local developmental cues and possibly cell-to-cell contact between
CD34+ HSPCs and MS5_FS12. To this end, we engrafted mice
with two distal organoids, one containing MS5_CTRL and the
second one containing MS5_FS12. We found that cDC1, cDC2,
and pre/AS-DCs were selectively expanded in MS5_FS12 plugs
(Fig. 6f and Supplementary Fig. 6c). On the contrary, pDC were
not significantly increased in the same comparison (Fig. 6f and
Supplementary Fig. 6c). We conclude that local cues associated to
the MS5_FS12 niche control cDC lineage commitment. In
support of this view, we could not detect a systemic increase in
the levels of serum FLT3L in mice carrying engineered stromal
cell plugs (Fig. 6g). Accordingly, spleen resident murine cDCs did
not expand upon MS5_FS12 engraftment, while they massively
do so upon administration of recombinant soluble human FLT3L
(Fig. 6g). Together with the two-plugs experiments (Fig. 6f), these
observations suggest that most of the FLT3L aegis relies on its
membrane-bound form delivered in the context of eMSCs. Of
note, administration of recombinant soluble FLT3L was poorly
efficient at expanding human DCs populations in Matrigel
organoids formed with control stromal cells (Fig. 6g). This
demonstrates the superiority of local, cell-associated cues (i.e.,
MS5_FS12) to achieve the expansion of human cDCs in the
dermis of NSG mice.
A more extensive characterization of MS5_FS12 organoids
revealed the presence of myeloid lineages other than DCs, such as
CD14+CD16− monocyte-like cells and CD15+ granulocytes
(Fig. 6h and Supplementary Fig. 6d). Conversely, no lymphoid
specification was observed (Fig. 6h and Supplementary Fig. 6d).
Despite this broad spectrum of lineages, CD34+ HSPCs
represented the most abundant population at day 12 (Fig. 6h).
This observation suggests that the MS5_FS12 niche combines
HSPC maintenance with lineage commitment.
cDC2 generated in vivo faithfully align to blood cDC2. Finally,
we wanted to establish whether in vivo differentiated DCs in
MS5_FS12 organoids had a distinct phenotype from the subsets
generated in vitro in MS5_FS12 co-culture.
UMAP plots of CyTOF analysis revealed three major findings.
First, pre/AS-DCs represent a more abundant population in vivo
(Fig. 7a and Supplementary Fig. 7a). Second, both cDC1 generated
in vitro and in vivo fully align phenotypically, displaying a strong
expression of CADM1 and CD26 (Fig. 7a and Supplementary
Fig. 7a). Third, unlike cDC1, cDC2 generated in vivo exhibit
noticeable phenotypic differences. In vivo-generated cDC2 express
Fig. 4 Human DC generated in vitro align with circulating blood DC. a Hierarchical clustering of primary (n= 3 healthy donors) vs. in vitro-generated
(n= 3 cord blood donors) cDCs based on 17,791 genes after removing the “in vitro culture signature” (2000 genes) defined by pairwise comparison of
primary versus in vitro generated subsets. b GSEA using blood cDC1s (DC1>CD1c+) and CD1c+ cells (CD1c+>DC1) signatures generated from published
datasets60, as well as previously published signatures of blood cDC1 (DC1>ALL), cDC2 (DC2>ALL), and cDC3 (DC3>ALL)20. BubbleMap shows the
enrichment of each gene signature in the pairwise comparison of CD141+Clec9A+, CD1c+CD206−, and CD1c+CD206+ cells generated in vitro (FDR false
detection rate, NES normalized enrichment score). For single pairwise comparisons (top), statistical significance is defined by the FDR q-value calculated by
the GSEA software (www.broad.mit.edu/gsea) using default parameters. For multiple pairwise comparisons (bottom), the statistical significance was
further corrected for multiple testing by the BubbleMap module of BubbleGUM software. c Heatmaps of RNA-seq data displaying the expression of the top
50 genes of blood cDC1 and CD1c+ cells signatures in CD141+Clec9A+, CD1c+CD206−, and CD1c+CD206+ cells generated in vitro. Genes shared with
previously published signatures20 are highlighted in bold. d UMAP (Uniform Manifold Approximation and Projection) plots of CyTOF data from
CD45+HLA-DR+ cells differentiated in vitro using MS5_FS12 and MS5_CTRL as compared with cord blood PBMCs. Pie charts indicate the frequency of
each subset among the CD45+HLA-DR+ cells (mean of n= 2 cord blood donors in two independent experiments). e Relative expression of selected
markers in UMAP plots of CyTOF data from cells differentiated in vitro with MS5_FS12. f Heatmap of markers mean intensity in each subset identified in
MS5_FS12 cultures.
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higher levels of FcεRIa, CD172a, and CD5, while showing lower
expression of HLA-DR and CD86 (Fig. 7b and Supplementary
Fig. 7b). The specific phenotype conferred by the MS5_FS12 niche
education renders cDC2s more akin to their blood counterparts.
In order to compare extensively the transcriptional landscape of
in vivo (NSG organoids) generated DCs with primary DCs found
in human blood, we performed RNA-seq analysis on fluorescence-
activated cell sorting (FACS)-sorted cDC2s obtained after the
enzymatic digestion of MS5_FS12-containing plugs or purified
from human blood.
As previously observed for in vitro-generated cells, the
MS5_FS12 niche confers an in vivo imprinting resulting in the
differential expression of 2872 genes (up- or downregulated) in
in vivo versus ex vivo-isolated subsets (Supplementary Fig. 7c).
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Pathway analysis revealed that this in vivo bias was mainly due to
upregulation of genes associated with DNA replication, cell cycle
and proliferation (MYC, CDC6/7, POLA2, MCM6/7) (Supple-
mentary Fig. 7c and Supplementary Table 8).
Moreover, we found that: (i) AXL+Siglec6+ pre/AS-DCs
generated in vivo (or in vitro) align to their primary counterparts
and selectively express a signature that distinguish them from
bona fide pDCs (DAB2, CD22, ADLH2) (Fig. 7c). (ii) conversely,
AXL−Siglec6− bona fide pDCs generated in vivo (or in vitro)
align to their primary counterparts and express high levels of
markers distinguishing them from pre/AS-DCs (IRF7, GZMB,
TCF4, BCL11A) (Fig. 7c). (iii) cDC2s generated in vivo (in NSG
mice organoids carrying MS5_FS12) had higher levels of
similarity with blood cDC2s (including higher expression of
BTLA, FCER1A) (Figs. 7b, d, e). Recently, both CD5+ and CD5−
cDC2s subsets have been reported in human blood62,63 and we
found that in vivo generated cDC2s aligned particularly well with
blood CD5+ cDC2s (with the expression of CD5, CD2) (Figs. 7b,
e). By contrast, in vitro-generated cDC2s expressed high levels of
activation genes such MHC molecules (HLA-DR, DQ), co-
stimulatory molecules (CD80, CD40), activation markers (ETS2,
CCR6, CCR7, CXCL13, CCL22) (Figs. 7e, f) and genes associated
with type I and type II interferon pathways (STAT1, IRF9, IGS15,
GBP1) (Supplementary Fig. 7d and Supplementary Table 9).
All together, we conclude that MS5_FS12-containing organoids
provide a unique scaffold for the specification and commitment
of the DC lineage. This unique and versatile system bypasses the
limitation of in vitro cultures, which generated inefficiently pre/
AS-DCs and biased the differentiation of cDC2s toward an
activated phenotype. Collectively, MS5_FS12 organoids faithfully
recapitulate the differentiation of not only pDCs, cDC1s, and
cDC2s but also pre/AS-DCs, and support the development of
cDC2s displaying an unattained level of similarity with their
human blood counterparts.
In vitro and in vivo cDC2 functionally align to blood cDC2. In
the last set of experiments, we aimed at functionally validate cord
blood-derived cDC generated in the MS5_FS12 stromal niche.
Moreover, we also assessed whether the phenotypic differences
observed in cDC2 generated in vitro and in vivo may impact their
function.
We first confirmed in vitro the responsiveness of cord blood-
derived cDC2 to TLR agonists expressed in human circulating
cDC2, as demonstrated by the upregulation of maturation
markers (i.e., HLA-DR, CD86, and CD83) in response to TLR4
(LPS) and TLR8 (VTX-2337) stimulation (Fig. 8a). We then
performed a mixed lymphocyte reaction (MLR) by co-culturing
CTV-labeled allogeneic naive T cells together with FACS-sorted
cDC subsets (Supplementary Fig. 8a) activated overnight with a
TLR agonists cocktail comprising of LPS (TLR4), R848 (TLR7/8)
and Poly(I:C) (TLR3). After 7 days of culture, we observed that
both in vitro and in vivo-generated cDC2 and pre/AS-DC were
capable to efficiently induce CD4+ naive T-cell proliferation
(Fig. 8b), as expected and reported for circulating blood
cDC212,20 (Supplementary Fig. 8b). Conversely, pDC were
significantly less effective on triggering T-cell activation, as
shown by the consistent reduction in the frequency of dividing
CD4+ T cells when compared with cDC2 and pre/AS-DC
(Fig. 8b).
Importantly, only cDC2 were able to produce high amounts of
T-cell-polarizing cytokines in response to TLR stimulation, as
demonstrated by intracellular TNFα and IL-12 detection by flow
cytometry (Fig. 8c). All these features demonstrate that cDC2s,
pDCs and pre/AS-DCs functionally align to their in vivo
counterparts as previously described in the literature12,20.
Collectively, our data suggest that: (i) both in vitro and in vivo
differentiated cDC2 are equally capable to induce CD4+ T cells
activation and produce large amounts of TNF-α and IL-12; (ii)
pre/AS-DC are as efficient as cDC2 in activating allogeneic naive
CD4+ T cells in vitro, a distinctive feature that clearly separate
them from the pDC lineage; (iii) despite their ability to induce
CD4+ T-cell proliferation in MLR settings, pre/AS-DC do not
produce high levels of cytokines commonly associated with cDC2
function, such as TNF-α or IL-12.
Discussion
Over the last two decades, DC-based strategies have been pro-
posed for the therapeutic vaccination against cancer, including (i)
non-targeted protein-based vaccines captured by DCs in vivo, (ii)
specific targeting of DC subsets with mAb coupled to tumor
antigens64 and (iii) antigen loading of ex-vivo-generated DCs3. In
this context, experimental models recapitulating the development
of human DC subsets are crucially needed.
Here we describe a novel approach to model human DC
development from CD34+ HSPCs both in vitro and in vivo. To
this end, we primarily focused on the physiological niches where
human DCs differentiate and maintain: a central bone marrow
niche where DC progenitors are specified and peripheral niches
in the lymph nodes where DCs reside.
Previous studies have shown that the cell-to-cell interaction
with membrane-bound factors expressed by the niche micro-
environment plays an essential role in HSPCs maintenance and
expansion21,22,65,66. Alternative splicing of human and murine
SCF transcript results in the synthesis of both a soluble and a
membrane-bound non-cleavable form of the protein. Interest-
ingly, the secreted form of SCF/KITLG is not sufficient for the
Fig. 5 Engineered stromal niches support HSPC maintenance in vivo. a Experimental strategy for an in vivo synthetic niche. Human HSPCs were injected
subcutaneously along with MS5_FS12 in a basement membrane matrix (Matrigel) preparation. b Hematoxylin–eosin staining of subcutaneous organoids at
day 12. Arrows show clusters of Matrigel-embedded cells. Scale bar represents 500 μm (left) and 250 μm (right). c Flow cytometry analysis at day 12 of
Matrigel organoids containing either MS5_CTRL or MS5_FS12 cells. Absolute number and frequency of human CD45+ cells recovered are summarized in
bar graphs (n= 13 cord blood donors in 6 independent experiments; **p < 0.01, two-tailed paired Student’s t-test). d Experimental strategy and
quantification of human CD45+ cells recovered from physically separated plugs containing either MS5_CTRL or MS5_FS12 cells injected in the same
recipient (n= 3 cord blood donors in one experiment; two-tailed paired Student’s t-test). e Immunofluorescence staining of plug sections displaying the
interaction of GFP+ MS5_FS12 (green) with human CD45+ cells (red). Human hematopoietic progenitors were also identified as CD45+ (red) CD34+
(blue) cells in MS5_FS12 plugs. Nuclei were stained with Hoechst (blue). Arrows show interaction of human CD45+ leukocytes with GFP+ MS5_FS12.
Scale bar represents 100 μm (left panel) and 20 μm (right panel). Similar results were observed in n= 5 Matrigel organoids. The presence of GFP+ stromal
cells in Matrigel organoids at day 12 was further confirmed by flow cytometry (n= 15 independent organoids). f Visualization of mouse CD31+ endothelial
cells by immunofluorescence. Fixed sections were stained for human CD45 (green) and mouse CD31 (red). Nuclei were stained with Hoechst (blue). Scale
bar represents 100 μm (left panel) and 50 μm (right panel). Similar results were observed in n= 5 Matrigel organoids. The presence of mouse CD31+ cells
was further confirmed by flow cytomery. Data are presented as floating bars ranging from min to max and line represents median (c, d) or scatter plots
with mean ± SEM (e).
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establishment of a functional niche in murine bone marrow21,22,
whereas the expression of human membrane-bound SCF is suf-
ficient to support human myeloid development in humanized
mice66. We therefore wanted to test whether a similar relation-
ship might exist between the soluble and membrane-bound forms
of human FLT3L. Consistent with this hypothesis, the expression
of transmembrane FLT3L in mesenchymal stromal cells (MS5_F)
improved the efficiency of DC differentiation in vitro, as com-
pared to its soluble form (MS5+ recFL). Moreover, the engraft-
ment of distal organoids (MS5_CTRL vs. MS5_FS12) together
with the comparison of local (membrane-bound) vs. systemic
(soluble) delivery of human FLT3L in vivo, supported the notion
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that cell-associated FLT3L delivered by engineered stromal cells
significantly improves the development of human DCs in
NSG mice.
Several protocols have been proposed for the in vitro differ-
entiation of human cDCs from CD34+ HSPCs7,37–39,46,47.
In vitro-differentiated cDC1s have been shown to fully recapi-
tulate both the phenotype and function of circulating bona fide
blood cDC1s8,38,46,47 including high levels of IRF8 expression and
Batf3-dependency in vitro13, as well as IRF8-dependancy both
in vivo67 and in vitro46. Conversely, several aspects have limited
an exhaustive validation of in vitro generated CD1c+ cDC2-like
cells such as the expression of CD147, the transcriptional align-
ment with monocyte-derived DCs38 or the lack of a high-
dimensional phenotypic characterization46,47.
Here we described a system (MS5_FS12), which efficiently
supports the differentiation of both CD141+Clec9A+ cDC1s and
CD14−CD1c+ cDC2s. However, cDC2s generated in MS5_FS12
cultures only partially recapitulate the phenotype of circulating
blood cDC2s, as suggested by the lack of expression of cDC2-
specific markers such as FcεRIa and CD5. Nevertheless, engi-
neered MSCs display the unique advantage of being suitable for
in vivo applications.
Immunodeficient mice provide a unique system to model the
onset of human immune responses in realistic settings68. How-
ever, a reliable method to achieve the differentiation of human
DCs in vivo has not been described, yet. Current protocols rely on
the engraftment of human CD34+ HSPCs in sub-lethally irra-
diated immunodeficient mice (humanized mice). This strategy
has not been successful in the generation of well-characterized
circulating DC subsets68. Administration of supraphysiological
levels of recombinant FLT3L has been shown to stimulate cDC
differentiation upon reconstitution of NSG28,48 or Flt3−/−
BRGS49 mice with human CD34+ HSPCs. However, the phe-
notype of CD141+ cDC1s and CD1c+ cDC2s was poorly char-
acterized and, despite exceptions50, tissue DCs were not generally
investigated. These aspects represent an important limitation by
precluding, for instance, the modeling of skin vaccination.
Alternatively, transgenic mice expressing human GM-CSF and
IL-3 (in the presence or absence of human SCF), either
constitutively69,70 or by replacing their murine counterparts
(knock-in)71, have been generated. Despite displaying higher
levels of myeloid reconstitution, as well as the presence of human
alveolar macrophages in the lungs of humanized mice71, this
approach did not improve the development of human cDCs in
lymphoid and non-lymphoid tissues of engrafted animals.
We demonstrated that MS5_FS12 support the differentiation of
human cDCs in vivo in subcutaneous organoids in NSG mice.
High-dimensional mass cytometry (Cytof) and transcriptomic
(RNA-seq) analysis of in vivo generated cells confirmed their
phenotypic and transcriptional alignment to circulating blood
cDC1s and cDC2s. More importantly, cDC2s generated in vivo
better resemble their physiologically circulating counterparts by
expressing higher levels of FcεRIa, CD172a, CD5, CD2, and
BTLA when compared to in vitro differentiated cells. The lower
expression of activation markers such as CD86, CD80 and MHC
molecules also suggests that in vivo cDC2s displayed a less mature
phenotype than in vitro-generated cells.
Moreover, MS5_FS12 niche was capable of supporting the local
maintenance and expansion of human HSPCs as well as pre/AS-
DCs, resulting in the persistence of a long-lasting source of
progenitors capable of undergoing DC differentiation. To our
knowledge, this is the first time that a well-characterized system
supporting the development of human pre/AS-DC is reported.
Collectively, we have demonstrated that the engineered stromal
cells MS5_FS12 give rise to a synthetic hematopoietic niche when
injected subcutaneously in NSG mice. The niche microenviron-
ment efficiently supports the expansion of CD34+ HSPCs and
human DCs subsets (cDC1, cDC2, and pre/AS-DC) can be
detected as early as day 12 in a radiation-free environment.
Importantly, in vitro culture system imposes a certain level of
spontaneous activation that is not found in primary circulating
blood DCs. Differentiation of human cDCs within humanized
mice limit this phenomenon to a level closer to the maturation
state of circulating primary cDCs. Hence, this approach repre-
sents a versatile system to study human DC development and
function in vivo.
Methods
Mice. All in vivo experiments were performed using NOD.Cg-Prdcscid Il2rgtm1Wjl/
SzJ (NSG) mice (JAX #005557). All mice were used between 8 and 12 weeks of age.
They were maintained in specific-pathogen-free conditions and handled according
to protocols approved by the UK Home Office.
Generation of engineered MSCs. Human FLT3L, SCF, and TPO were amplified
by PCR from cDNA expression plasmids (Origene) and cloned into pMX retroviral
vectors (vectors details in Supplementary Table 1). Lentiviral vector pBABE-puro-
SDF-1 alpha was a gift from Bob Weinberg (Addgene plasmid #12270)72. Viral
particles were generated using the retroviral packaging plasmid pCL-Ampho and a
second generation lentiviral packaging system (psPAX2 and pMD2.G), respec-
tively. MS5 cells were first transduced with CXCL12 lentiviral vector and selected
using 15 μg/ml of Puromycin (Thermo Fisher). Then, a combination of single or
multiple cytokines were used to transduce MS5 cells as illustrated in
Fig. 6 The MS5_FS12 niche supports human DC development in vivo. a Flow cytometry of Matrigel organoids containing either MS5_CTRL or MS5_FS12.
Graphs show frequency of cDC1 and cDC2 within CD45+ cells (n= 14 donors in 6 independent experiments). **p < 0.01 ****p < 0.0001, two-tailed paired
Student’s t-test. b Immunofluorescence of MS5_FS12 organoids sections stained for huCD45+ (green) and Clec9A+ (red) or and CD1c+ (red). Nuclei
stained with Hoechst (blue). Scale bar= 50 μm (n= 2 Matrigel organoids). c Left: Flow cytometry and quantification of CD123+CD303/4+ cells in
MS5_CTRL and MS5_FS12 organoids (n= 14 donors in 6 independent experiments. Two-tailed paired Student’s t-test). Middle: Gating strategy
discriminating AXL−CD327lo/− pDC and AXL+CD327+ pre/AS-DC within CD123+CD45RA+ cells in MS5_FS12 organoids. Bar graph illustrates frequency
of each subset within CD123+CD45RA+ cells (n= 4 donors). Right: Frequency of pre/AS-DC within CD45+ cells in MS5_CTRL vs. MS5_FS12 organoids
(n= 7 donors in 4 independent experiments). *p < 0.05, two-tailed paired Student’s t-test. d GSEA of pDC and pre/AS-DC using published gene
signatures20. Statistical significance defined by the FDR q-value calculated by GSEA software (www.broad.mit.edu/gsea) using default parameters.
e CyTOF analysis comparing CD45+HLA-DR+ cells in MS5_FS12 and MS5_CTRL organoids. Pie charts display frequency within CD45+HLA-DR+ cells
(mean of n= 2 donors in 2 independent experiments). f Frequency of cDC1, cDC2, pDC, pre/AS-DC and total CD123+CD45RA+ cells recovered from
physically separated plugs containing either MS5_CTRL or MS5_FS12 in the same recipient (n= 3 donors in one experiment). *p < 0.05, two-tailed paired
Student’s t-test. g NSG mice injected subcutaneously either with MS5_CTRL or MS5_FS12 stromal cells. Human recombinant FLT3L administered intra-
peritoneum to mice bearing MS5_CTRL plugs (10 μg/mouse/injection) (MS5_CTRL+recFL). Frequency of human cDC1, cDC2, and pDC in subcutaneous
organoids (left) and murine cDC1, cDC2 and pDC in the spleen (center) were reported. Circulating recombinant FLT3L levels were measured by ELISA
(right). n= 4 mice/group in 2 independent experiments. *p < 0.05, **p < 0.01, one-way ANOVA test with Dunnett’s T3 multiple comparisons. h Frequency
of differentiated subsets within huCD45+ cells in MS5_FS12 plugs at day 12. The number of biological replicates (n) is reported. Data presented as floating
bars ranging from min to max and line represents median (a, c, f, h) or as bar graphs with mean ± SEM (c, g).
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Fig. 7 cDC2 generated in vivo faithfully align to blood cDC2. a UMAP plots of CyTOF data comparing CD45+HLA-DR+ cells generated using
MS5_FS12 stromal cells either in vitro or in vivo. Relative expression of selected markers is shown for each condition. b Relative expression of selected
markers highlighting the phenotypic differences between cDC2s generated in vitro and in vivo using MS5_FS12 stromal cells. c Heatmap displaying gene
expression of the top ten genes of blood pDC and AS-DC published signatures20 in pDC and pre/AS-DC generated in vitro, in vivo, and isolated from blood
PBMC (n= 2 independent donors for pDC and pre/AS-DC generated in vivo and n= 3 independent donors for pDC and pre/AS-DC generated in vitro or
isolated from peripheral blood). d Heatmap displaying gene expression of the blood cDC2 published signature20 in cDC2 cells generated in vitro, in vivo
and isolated from blood PBMC (n= 3 independent donors). e Volcano plot showing differentially expressed genes between in vitro and in vivo generated
cDC2 (Log2FC > 1.5, adjusted p-value < 0.05). Statistical significance was calculated using Wald test with a Benjamin–Hochberg p-value correction (n= 3
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Supplementary Fig. 2a. Cells expressing human membrane-bound FLT3L and SCF
were sorted according to antibody staining of the transmembrane proteins (anti-
bodies listed in Supplementary Table 3). TPO-expressing cells were sorted
according to the expression of mCherry reporter.
Flow cytometry and fluorescent-activated cell sorting. Extracellular staining of
cells was preformed in FACS buffer, consisting in phosphate-buffered saline (PBS)
(Life Technologies), 1% bovine serum albumin (BSA) (Apollo Scientific) and 2 mM
EDTA (Life Technologies). For intracellular staining, samples were fixed and
permeabilized using the Cytofix/CytopermTM kit (BD Biosciences) according to
manufacturers’ instructions. Antibodies used in all experiments are listed in Sup-
plementary Table 3. Flow cytometry analysis was performed on LSR Fortessa II
(BD Biosciences, BD FACSDiva Software) and data were analyzed using FlowJo
software (TreeStar, version 10.2). Cell sorting was performed using AriaII (BD
Biosciences, BD FACSDiva Software).
Cell lines maintenance and primary cells isolation. MS551 and eMSC lines were
cultured in IMDM (Life Technologies) supplemented with 10% heat-inactivated
fetal bovine serum (FBS) (Life Technologies), penicillin/streptomycin (Life Tech-
nologies), 50 μM β-mercaptoethanol (Life Technologies), and maintained at 37 °C
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5% CO2. OP9 and OP9_FLT3L were cultured in complete α-MEM (Life Tech-
nologies) supplemented with 20% not heat-inactivated FBS, penicillin/streptomy-
cin, 50 μM β-mercaptoethanol and maintained at 37 °C 5% CO2.
Cord blood units were obtained from Anthony Nolan Cell Therapy Centre
(ANCTC). Peripheral blood mononuclear cells (PBMCs) were isolated by gradient
centrifugation using Ficoll-Paque (GE Healthcare) and CD34+ hematopoietic
progenitors were isolated using CD34 MicroBead Kit UltraPure (Miltenyi Biotec).
Adult peripheral blood was obtained from healthy volunteers from NHS Blood
and Transplant. PBMCs were isolated by Ficoll-Paque gradient centrifugation.
Cells were collected in FACS buffer and used for downstream applications.
Human dendritic cell differentiation in vitro. For in vitro differentiation of
human DCs, MS5, OP9 or eMSCs were seeded in a 96-well plate (flat bottom) at a
density of 104 cells/well. The following day, 104 cord blood-derived CD34+ cells/
well were seeded on top of stromal cells in complete IMDM (10% heat-inactivated
FBS, penicillin/streptomycin, 50 μM β-mercaptoethanol) and maintained at 37 °C
5% CO2. Half of the medium was replaced at day 5 and 10, and cells were collected
with a solution of PBS 5 mM EDTA (at 4 °C) at day 15 for flow cytometry analysis.
For recombinant FLT3L experiments, human FLT3L (Celldex) 100 ng/ml was used.
For transwell experiments, 24-well plates with 0.4 μm pores Transwell® inserts
(Corning) were used. Stromal cells were plated at a density of 105 cells/well and 7 ×
104 cord blood-derived CD34+ progenitors were added the following day in each
well. Half of the medium was replaced in both the top and bottom well at day 5 and
10. For GM-CSF blocking experiments, 2 μg/ml human GM-CSF neutralizing
antibody (R&D catalog number #AF-215-SP) and isotype control (R&D catalog
number #AB-108-C) were added to the culture medium. The presence of human
GM-CSF in the supernatant of eMSCs co-cultures with CD34+ HSPCs was
assessed by enzyme-linked immunosorbent assay (ELISA) using the human GM-
CSF ELISA MAX kit (Biolegend) as per manufacturer’s instructions.
RNA-seq and data processing. RNA-seq analysis was performed in two inde-
pendent experiments. In the first experiment, human cDC1s and cDC2s from
peripheral blood of n= 3 healthy individuals and in vitro generated CD141
+Clec9A+, CD14-CD1c+CD206−, and CD14−CD1c+CD206+ cells from n= 3
independent cord blood donors were FACS sorted. Up to 100 cells/subset were
collected in lysis buffer (Takara Clontech) containing RNAse inhibitors. RNA-seq
libraries were prepared using Labcyte Echo 525 contactless liquid handling system
(Labcyte, Inc.). In brief, ERCC mix (Thermo Fisher) was added to each sample and
first strand full-length cDNA was generated with a modified protocol of the
SMARTseq v4 Ultra Low Input RNA Kit (Takara Clontech) using poly dT primers
and a template switching oligo. Full-length cDNA was amplified using SeqAmp™
DNA Polymerase (Takara Clontech). 12 ng of amplified cDNA from each sample
was used to generate non-stranded RNA libraries using a modified protocol of the
Ovation Ultralow System V2 1-96 kit (NuGEN). In brief, amplified cDNA was
fragmented through sonication on Covaris E220 (Covaris, Inc.), repaired and
polished followed by ligation of indexed adapters. Adapter ligated cDNA were
pooled before final amplification to add flow cell primers. Libraries were sequenced
on HiSeq2500 (Illumina Cambridge) for 100 cycles PE in Rapid mode. The raw
sequencing data was initially processed using open source, web-based platform
Galaxy (version 18.05.rc1) (https://usegalaxy.org). Reads were filtered for quality
with more than 80% of the sequence having quality score > 33 using FastQC tool.
Mapping against reference genome was performed with Hisat2 to the hg38 human
genome. Adapter sequences were detected automatically with TrimGalore!. Reads
under 20 bp were discarded. All processed sequencing files were imported in
Partek® Flow® software (Partek, Inc., build 7.0.18.0514) and the gene count data
was normalized using FPKM.
In the second experiment, human CD5− cDC2, CD5+ cDC2, pDC, and pre/AS-
DC from peripheral blood of n= 3 healthy individuals and cDC2, pDC and pre/
AS-DC generated both in vivo and in vitro from n= 2/3 independent cord blood
donors were FACS sorted. Between 100 and 1000 cells/subset were collected in
TRIzol® (Thermo Fisher) and stored at -80°C. Frozen samples were shipped to
GENEWIZ® where they were processed. RNA was extracted and libraries were
prepared using an ultralow input RNA library preparation kit (Illumina). Libraries
were sequenced on HiSeq2500 (Illumina).
The raw sequencing data was initially aligned on the human reference genome
hg38 using STAR aligner (v2.5.3a)73 (parameters: --outFilterType BySJout --
outFilterMultimapNmax 20 --alignSJoverhangMin 8
--alignSJDBoverhangMin 1 --
outFilterMismatchNmax 999 --outFilterMismatchNoerLmax 0.04
--alignIntronMin 20 --
alignIntronMax 1000000 --alignMatesGapMax 1000000 --outSAMprimaryFlag
OneBestScore --outMultimapperOrder Random --outSAMattributes All). Raw
read counts matrix was also made with STAR (using the parameter --quantMode
GeneCounts).
RNA-sequencing analysis. The average gene expression of n= 3 blood donors for
cDC1s, n= 2 blood donors for cDC2 and n= 3 cord blood units for in vitro
generated subsets were used for RNA-seq data analysis.
Hierarchical clustering was performed in Morpheus (Broad Institute, https://
software.broadinstitute.org/morpheus/) using one minus Pearson’s correlation and
average linkage.
GSEA (www.broad.mit.edu/gsea)58 was used to assess the expression of gene
signatures specific for blood cDC1, cDC2, DC3, pDC, and AS-DC in in vitro and
in vivo generated subsets. To simultaneously visualize pairwise comparisons of
transcriptomes from cord blood-derived cDCs, the BubbleMap module of
BubbleGum59 was used. Results were considered significant when the p-value was
below 0.05 and the FDR (q) value was below 0.25. The GSEA was performed using
previously published gene signatures defining blood cDC1, cDC2, DC3, pDC, and
AS-DC20, as well as newly generated signatures using the GeneSign module of
BubbleMap59 (Supplementary Table 6). Briefly, the transciptome of blood cDC1s
and blood CD1c+ cells was taken from previously published datasets60.
cDC1>CD1c+ and CD1c+>cDC1 signatures were defined using the “Min(test) vs.
Max(ref)” statistical method with a minimal linear fold change= 2 and a maximal
FDR= 0.01.
Heatmaps displaying the expression pattern of gene signatures for cDC1, CD1c
+ cells, pDC, AS-DC, and cDC2 were generated using Morpheus (Broad Institute,
https://software.broadinstitute.org/morpheus/).
The 2000 genes defining the “in vitro culture imprinting” were identified using
Morpheus as the mean difference of expression values between two groups: the
in vitro generated cells (including cDC1, cDC2 CD206− and cDC2 CD206+)
versus ex vivo-isolated subsets (blood cDC1 and blood cDC2).
The 2872 genes defining the “in vivo signature” were identified by DEG analysis
using the R package DESeq2 (version 1.24.0)74 with a Benjamin–Hochberg p-value
correction75 (Log2FC > 1.5, adjusted p-value < 0.01). The volcano plot displaying
the differentially expressed genes between in vivo and in vitro differentiated cDC2
was generated using R package ggplot2 (version 3.2.1)76 (Log2FC > 1.5, adjusted
p-value < 0.05). All the analysis from the raw counts matrix were performed in
Rstudio (1.2.5001) using the version 3.6.1 of R. Pathway analysis was performed
using ConsensusPathDB (cpdb.molgen.mpg.de)77 and WikiPathways database.
Mass cytometry acquisition and data analysis. For mass cytometry, pre-
conjugated or purified antibodies were obtained from Invitrogen, Fluidigm (pre-
conjugated antibodies), Biolegend, eBioscience, Becton Dickinson, or R&D Systems
as listed in Supplementary Table 5. For some markers, fluorophore- or biotin-
conjugated antibodies were used as primary antibodies, followed by secondary
labeling with anti-fluorophore metal-conjugated antibodies (such as the anti-FITC
clone FIT-22) or metal-conjugated streptavidin, produced as previously descri-
bed78. Briefly, 3 × 106 cells/well in a U-bottom 96-well plate (BD Falcon) were
washed once with 200 µL FACS buffer (4% FBS, 2 mM EDTA, 0.05% Azide in 1×
PBS) and then stained with 100 µL 200 µM cisplatin (Sigma-Aldrich) for 5 min on
ice to exclude dead cells. Cells were then incubated with anti-CADM1-biotin
antibody in a 50 µL reaction for 30 min on ice. Cells were washed twice with FACS
buffer and incubated with 50 µL heavy-metal isotope-conjugated secondary mAb
cocktail for 30 min on ice. Cells were then washed twice with FACS buffer and once
with PBS before fixation with 200 µL 2% paraformaldehyde (PFA; Electron
Microscopy Sciences) in PBS overnight or longer. Following fixation, the cells were
pelleted and resuspended in 200 μL 1X permeabilization buffer (Biolegend) for 5
minutes at room temperature to enable intracellular labeling. Cells were then
Fig. 8 In vitro and in vivo cDC2 functionally align to blood cDC2. a Histograms showing upregulation of activation markers HLA-DR, CD86 and CD83 in
in vitro-differentiated cDC2 in response to TLR4 (LPS) and TLR8 (VTX-2337) overnight (16 h) stimulation. b Representative FACS plots and quantification
of mixed lymphocyte reaction (MLR) using in vitro and in vivo differentiated cDC2, pDC, and pre/AS-DC. FACS-sorted DC subsets were activated
overnight (16 h) using a TLR agonist cocktail (LPS 10 ng/ml, R848 1 μg/ml and Poly(I:C) 25 μg/ml) and co-cultured with CTV-labeled naive T cells for
7 days (n= 2 independent donors for pDC generated in vivo and pre/AS-DC generated in vitro and in vivo and n= 3 independent donors for in vitro and
in vivo generated cDC2 and in vitro generated pDC in two independent experiments). **p < 0.01, one-way ANOVA test with Holm–Sidak’s multiple
comparisons. c Intracellular flow cytometry analysis of TNFα and IL-12 expression in in vitro and in vivo-differentiated DC subsets upon overnight (16 h)
stimulation with TLR agonist cocktail (LPS 10 ng/ml, R848 1 μg/ml, and Poly(I:C) 25μg/ml) as compared to unstimulated cells (NT). n= 4 independent
cord blood donors. **p < 0.01, ***p < 0.001, one-way ANOVA test Holm–Sidak’s multiple comparisons. Data are presented as floating bars ranging from
min to max and line represents median b or as bar graphs with mean ± SEM (c).
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incubated with metal-conjugated anti-CD68 in a 50 µL reaction for 30 min on ice.
Finally, the cells were washed once with permeabilization buffer and then with PBS
before barcoding.
Bromoacetamidobenzyl-EDTA (BABE)-linked metal barcodes were prepared
by dissolving BABE (Dojindo) in 100 mM HEPES buffer (Gibco) to a final
concentration of 2 mM. Isotopically-purified PdCl2 (Trace Sciences Inc.) was then
added to the 2 mM BABE solution to a final concentration of 0.5 mM. Similarly,
DOTA-maleimide (DM)-linked metal barcodes were prepared by dissolving DM
(Macrocyclics) in L buffer (MAXPAR) to a final concentration of 1 mM. RhCl3
(Sigma) and isotopically-purified LnCl3 was then added to the DM solution at
0.5 mM final concentration. Six metal barcodes were used: BABE-Pd-102, BABE-
Pd-104, BABE-Pd-106, BABE-Pd-108, BABE-Pd-110, and DM-Ln-113.
All BABE and DM-metal solution mixtures were immediately snap-frozen in
liquid nitrogen and stored at −80 °C. A unique dual combination of barcodes was
chosen to stain each sample. Barcode Pd-102 was used at 1:4000 dilution, P d-104
at 1:2000, Pd-106 and Pd-108 at 1:1000, Pd-110 and Ln-113 at 1:500. Cells were
incubated with 100 µL barcode in PBS for 30 min on ice, washed in
permeabilization buffer and then incubated in FACS buffer for 10 min on ice. Cells
were then pelleted and resuspended in 100 µL nucleic acid Ir-Intercalator
(MAXPAR) in 2% PFA/PBS (1:2000), at room temperature. After 20 min, cells
were washed twice with FACS buffer and twice with water before a final
resuspension in water. In each set, the cells were pooled from all samples, counted,
and diluted to 0.5×106 cells/mL. EQ Four Element Calibration Beads (DVS Science,
Fluidigm) were added at a 1% concentration prior to acquisition. Cell data were
acquired and analyzed using a CyTOF Mass cytometer (Fluidigm).
The CyTOF data were exported in a conventional flow cytometry file (.fcs)
format and normalized using previously described software79. Events with zero
values were randomly assigned a value between 0 and –1 using a custom R script
employed in a previous version of mass cytometry software80. Cells for each
barcode were deconvolved using the Boolean gating algorithm within FlowJo. The
CD45+Lin (CD7/CD14/CD15/CD16/CD19/CD34)-HLA-DR+ population of
PBMC were gated using FlowJo and exported as an.fcs file. Marker expression
values were transformed using the logicle transformation function81. Random sub-
sampling without replacement was performed to select 20,000 cell events.
The transformed values of sub-sampled cell events were then subjected to
UMAP dimension reduction61,82 using all markers. We used the 2.4.0 release of
UMAP, implemented in Python, but executed through the reticulate R package to
interface R objects with Python. For both mass-cytometry datasets we used UMAP
using 15 nearest neighbors (nn), a min_dist of 0.2 and euclidean distance.
Heatmaps displaying mean intensity values of CyTOF data were generated
using Morpheus (Broad Institute, https://software.broadinstitute.org/morpheus/).
Human dendritic cell differentiation in vivo. Human cord blood-derived CD34+
hematopoietic cells (5–15 × 104 cells/plug) were injected subcutaneously along with
engineered stromal cells (1 : 1 to 1 : 5 ratio HSPC/MS5) in 200 μl of ice-cold
Matrigel® (BD Biosciences). Mice were killed at day 12 of differentiation by cervical
dislocation and Matrigel® plugs were collected. Subcutaneous Matrigel® plugs
were recovered, cut in pieces and incubated in HBSS (Life Technologies) 1% FBS,
0.37 U/ml Collagenase D (Roche), 10 μg/ml DNaseI (Roche), and 1 mg/ml Dispase
(Sigma-Aldrich) for 30 minutes at 37 °C. After digestion, plugs were smashed on a
100 μm strainer (Corning) and cells were collected and resuspended in FACS
buffer for flow cytometry analysis.
Histology. Matrigel plugs were fixed with 1% PFA (Alfa Aesar) for 1 hr at 4 °C,
washed and incubated in 34% sucrose solution (Sigma-Aldrich) overnight at 4 °C.
Plugs were embedded in Cryomatrix (Thermo Fisher) and frozen for cryostat
sectioning (9 μm-thick). Sections were permeabilized using 0.5% saponin (Sigma-
Aldrich), 2% BSA (Sigma-Aldrich), 1% FBS (Life Technologies) for 30 min at room
temperature. For human DCs staining, plug sections were incubated with 1% rat
anti-mouse CD16/32 (homemade) for 30 min to block unspecific binding sites.
Sections were labeled overnight at 4 °C with mouse anti-human CD1c-PE (L161,
Biolegend) or mouse anti-human Clec9A-PE (8F9, Biolegend) followed by incu-
bation for 1 h at room temperature with goat anti-mouse Cy3 (Jackson laboratory).
After extensive washes, sections were labeled with mouse anti-human CD45-APC
(HI30, Biolegend) for 1 hr at room temperature. For human CD34+ progenitors
staining, plugs sections were labeled overnight with purified mouse anti-human
CD45 (HI30, Biolegend) followed by 1 hr incubation at room temperature with
goat anti-mouse Cy3. After extensive washes, sections were labeled with mouse
anti-human CD34−APC (561, Biolegend) for 1 h at room temperature. To detect
murine endothelial cells, sections were labeled with purified rat anti-mouse CD31
(MEC13.3, Biolegend) and mouse anti-human CD45 (HI30, Biolegend) overnight
followed by 1 h incubation at room temperature with goat anti-mouse Cy3
(Jackson laboratory) and goat anti-rat Cy5 (Jackson laboratory). All sections were
labeled with Hoechst (Molecular Probes, Thermo Fisher) for nuclei staining 5
minutes at room temperature and mounted with Prolong diamond (Thermo Sci-
entific). Slides were imaged using a SP5 (Leica Application Suite) and analyzed with
Fiji software.
Mixed lymphocyte reaction. Cord blood-derived DC subsets differentiated
in vitro and in vivo were FACS-sorted into a V bottom 96-well plate (Corning)
(104 cells/well) and activated overnight (16 h) using a TLR agonists cocktail con-
taining LPS 10 ng/ml, R848 1 μg/ml, and Poly(I:C) 25 μg/ml.
PBMCs were isolated by gradient centrifugation using Ficoll-Paque (GE
Healthcare) and labeled with Cell Trace Violet (Thermo Fisher) according to
manufacturer’s user guide. CTV-labeled T cells were then isolated using a Pan
naive T-cell isolation kit (Miltenyi Biotec) according to manufacturer’s instructions
and isolation purity (≥95%) was assessed by flow cytomery. Isolated naive T cells
(105 cells/well) were seeded together with FACS-sorted DC (1 : 10 ratio DC/T cells)
and incubated at 37 °C 5% CO2 for 7 days.
Statistical analysis. In all graphs each dot represents an independent cord blood
donor and lines represent the median value. The number of biological as well as
experimental replicates is indicated in figure legend. For each experiment, the
appropriate statistical test is stated in figure legend. Statistical significance was
defined as P < 0.05. All graphs and statistical analysis was performed using
GraphPad Prism.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Data that support the findings of this study have been deposited in NCBI’s Gene
Expression Omnibus (GEO) and are accessible through GEO accession codes GSE144435
[https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE144435] and GSE145803
[https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE145803].
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